Generic filters
Filter by content type
Taxonomy terms

STOK – Stoke Therapeutics Inc


Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month


Recommendation Rating







1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 51.1

Low: 24

High: 83

Total Analysts: 9

Company Profile

Stoke Therapeutics, Inc. is a biotechnology company focused on addressing the underlying causes of severe genetic diseases by upregulating protein expression with ribonucleic acid based medicines. The Company is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The Company’s STK-001, is for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Its STK-002 is a proprietary antisense oligonucleotide (ASO) in preclinical development for the treatment of Autosomal Dominant Optic Atrophy (ADOA). STK-002 is designed to upregulate OPA1 protein expression by leveraging the non-mutant copy of the OPA1 gene to restore OPA1 protein expression with the aim to stop or slow vision loss in patients with ADOA. The Company develops the precision medicine platform to target the underlying cause of a spectrum of genetic diseases in which the patient has healthy copy of a gene and mutated copy that fails to produce a protein essential to health.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan